comparemela.com

Latest Breaking News On - Anticipated milestones - Page 7 : comparemela.com

Will Celcuity s VIKTORIA-1 Hit The Target?

Shares of Celcuity Inc. (CELC) are down 34% from their 52-week high of $14.40, recorded in January of this year, to trade around $9..

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Vivani Medical Reports Second Quarter Financial Results and Provides Business Update

Vivani Medical Reports Second Quarter Financial Results and Provides Business Update

Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.